Hypothesis: cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology
Abstract
We sought biological pathways that explained discordance between Alzheimer's disease (AD) pathology and symptoms.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 09, 2019
- Source ID
- 10.1016/j.jalz.2019.05.007
Entities
People
- David Morgan
- John Breitner
- Judes Poirier
- Melissa Savard
- Pierre‐françois Meyer
- The Alzheimer’s Disease Neuroimaging Initiative*
Organizations
- AbbVie
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Chiron Corporation
- Douglas Mental Health University Institute
- Eisai
- Eli Lilly and Company
- GE HealthCare
- Hoffmann-La Roche
- Johnson & Johnson Pharmaceutical Research and Development
- Laboratoires Servier
- Lundbeck
- McGill University
- Merck & Co.
- Meso Scale Diagnostics (United States)
- Michigan State University
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- Northern California Institute for Research and Education
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- United States Department of Defense